Taken from the last Ann
All participants completing the Treatment Period of the study will be offered to the enter an open label extension
study of ATL1102 conducted under a separate protocol and will be given the highest dose tested in the study or
the highest dose considered generally safe and well tolerated in the study. This will serve to further increase the
safety and efficacy database.
Chart, page-1269
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.001(1.25%) |
Mkt cap ! $83.73M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.2¢ | 7.9¢ | $153.8K | 1.914M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 927041 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 218878 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |